GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anixa Biosciences Inc (NAS:ANIX) » Definitions » Cyclically Adjusted PB Ratio

Anixa Biosciences (Anixa Biosciences) Cyclically Adjusted PB Ratio : 4.05 (As of Jun. 09, 2024)


View and export this data going back to 1989. Start your Free Trial

What is Anixa Biosciences Cyclically Adjusted PB Ratio?

As of today (2024-06-09), Anixa Biosciences's current share price is $2.55. Anixa Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Apr. 2024 was $0.63. Anixa Biosciences's Cyclically Adjusted PB Ratio for today is 4.05.

The historical rank and industry rank for Anixa Biosciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

ANIX' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.5   Med: 11.02   Max: 34.85
Current: 4.07

During the past years, Anixa Biosciences's highest Cyclically Adjusted PB Ratio was 34.85. The lowest was 1.50. And the median was 11.02.

ANIX's Cyclically Adjusted PB Ratio is ranked worse than
72.16% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs ANIX: 4.07

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Anixa Biosciences's adjusted book value per share data for the three months ended in Apr. 2024 was $0.738. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.63 for the trailing ten years ended in Apr. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Anixa Biosciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Anixa Biosciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anixa Biosciences Cyclically Adjusted PB Ratio Chart

Anixa Biosciences Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.23 10.53 17.36 13.67 5.82

Anixa Biosciences Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.64 7.07 5.82 7.78 4.74

Competitive Comparison of Anixa Biosciences's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Anixa Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Cyclically Adjusted PB Ratio falls into.



Anixa Biosciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Anixa Biosciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.55/0.63
=4.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Apr. 2024 is calculated as:

For example, Anixa Biosciences's adjusted Book Value per Share data for the three months ended in Apr. 2024 was:

Adj_Book=Book Value per Share/CPI of Apr. 2024 (Change)*Current CPI (Apr. 2024)
=0.738/131.7762*131.7762
=0.738

Current CPI (Apr. 2024) = 131.7762.

Anixa Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201407 0.014 100.520 0.018
201410 0.414 100.176 0.545
201501 0.819 98.604 1.095
201504 0.690 99.824 0.911
201507 0.625 100.691 0.818
201510 0.526 100.346 0.691
201601 0.373 99.957 0.492
201604 0.265 100.947 0.346
201607 0.177 101.524 0.230
201610 0.101 101.988 0.130
201701 -0.397 102.456 -0.511
201704 0.307 103.167 0.392
201707 0.363 103.278 0.463
201710 0.477 104.070 0.604
201801 0.387 104.578 0.488
201804 0.360 105.708 0.449
201807 0.338 106.324 0.419
201810 0.287 106.695 0.354
201901 0.281 106.200 0.349
201904 0.327 107.818 0.400
201907 0.288 108.250 0.351
201910 0.257 108.577 0.312
202001 0.261 108.841 0.316
202004 0.246 108.173 0.300
202007 0.364 109.318 0.439
202010 0.361 109.861 0.433
202101 0.519 110.364 0.620
202104 1.196 112.673 1.399
202107 1.218 115.183 1.393
202110 1.179 116.696 1.331
202201 1.127 118.619 1.252
202204 1.067 121.978 1.153
202207 1.034 125.002 1.090
202210 0.940 125.734 0.985
202301 0.899 126.223 0.939
202304 0.866 127.992 0.892
202307 0.823 128.974 0.841
202310 0.781 129.810 0.793
202401 0.775 130.124 0.785
202404 0.738 131.776 0.738

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Anixa Biosciences  (NAS:ANIX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Anixa Biosciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Anixa Biosciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anixa Biosciences (Anixa Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Executives
Amit Kumar director, officer: Chief Executive Officer C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Michael Catelani officer: COO & CFO 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Titterton Lewis H Jr director 6 AUTUMN LANE, SARATOGA SPRINGS NY 12866
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Emily Gottschalk director 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118
John J Monahan director
David Cavalier director C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Richard H Williams director C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108
Dale Fox director 929 NOWITA PLACE, VENICE CA 90291
Andrea Belz director 1011 ALTA VISTA DRIVE, ALTADENA CA 91001
Tisha Stender officer: Chief Operating Officer 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Robert Andrew Berman officer: President and CEO C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
John H. Roop officer: Sr. Vice President-Engineering C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Bruce F Johnson director 20 S. WACKER DR, CHICAGO IL 60606
Kent B. Williams director C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747